Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) has earned a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the company, reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $48.50.

In other Alkermes Plc news, CFO James M. Frates unloaded 15,000 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $41.37, for a total transaction of $620,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alkermes Plc (NASDAQ:ALKS) opened at 44.22 on Friday. Alkermes Plc has a 52-week low of $29.36 and a 52-week high of $54.25. The stock’s 50-day moving average is $44.68 and its 200-day moving average is $46.42. The company’s market cap is $6.448 billion.

Alkermes Plc (NASDAQ:ALKS) last announced its earnings results on Thursday, July 31st. The company reported $0.11 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter last year, the company posted $0.30 earnings per share. Alkermes Plc’s revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Alkermes Plc will post $0.27 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on ALKS shares. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Wednesday, August 6th. They now have a $45.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday, August 1st. Finally, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.